ANGPT2 and cancer: However, to date, there are no clinical trials that have used L1-10, but trebananib, an Ang-2 neutralizing peptide antibody, has been already tested as an additional therapy in advanced cancer diseases [65,66], revealing a good toxicity profile in patients, although the most frequent side effects were edema and ascites [65,66].